Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<p>Supplementary Figure S2. Percent reduction in B cell numbers and B cell/T cell ratios in human CD20 transgenic mice treated with obinutuzumab or rituximab in A, Spleen and B, Lymph nodes. C, Reduction in splenic marginal zone B cells in human CD20 transgenic mice treated with obinutuzumab or rituximab (n = 2 per group).</p>

Original publication

DOI

10.1158/1078-0432.25603704.v1

Type

Other

Publication Date

15/04/2024